BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 26694875)

  • 1. Therapeutic l-asparaginase: upstream, downstream and beyond.
    Lopes AM; Oliveira-Nascimento L; Ribeiro A; Tairum CA; Breyer CA; Oliveira MA; Monteiro G; Souza-Motta CM; Magalhães PO; Avendaño JG; Cavaco-Paulo AM; Mazzola PG; Rangel-Yagui CO; Sette LD; Converti A; Pessoa A
    Crit Rev Biotechnol; 2017 Feb; 37(1):82-99. PubMed ID: 26694875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
    Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced catalysis of L-asparaginase from Bacillus licheniformis by a rational redesign.
    Sudhir AP; Agarwaal VV; Dave BR; Patel DH; Subramanian RB
    Enzyme Microb Technol; 2016 May; 86():1-6. PubMed ID: 26992786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding targets for a metabolic therapy of cancer: L-asparaginase.
    Covini D; Tardito S; Bussolati O; Chiarelli LR; Pasquetto MV; Digilio R; Valentini G; Scotti C
    Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):4-13. PubMed ID: 21854356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme Engineering Strategies for the Bioenhancement of L-Asparaginase Used as a Biopharmaceutical.
    Miranda J; Lefin N; Beltran JF; Belén LH; Tsipa A; Farias JG; Zamorano M
    BioDrugs; 2023 Nov; 37(6):793-811. PubMed ID: 37698749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation, Purification, Characterisation and Application of L-ASNase: A Review.
    Paul T; Mondal A; Bandyopadhyay TK
    Recent Pat Biotechnol; 2019; 13(1):33-44. PubMed ID: 30318009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
    Avramis VI; Tiwari PN
    Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-function relationships and clinical applications of L-asparaginases.
    Labrou NE; Papageorgiou AC; Avramis VI
    Curr Med Chem; 2010; 17(20):2183-95. PubMed ID: 20423302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer.
    Costa-Silva TA; Costa IM; Biasoto HP; Lima GM; Silva C; Pessoa A; Monteiro G
    Blood Rev; 2020 Sep; 43():100651. PubMed ID: 32014342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monolith and coating enzymatic microreactors of L-asparaginase: kinetics study by MCE-LIF for potential application in acute lymphoblastic leukemia (ALL) treatment.
    Qiao J; Qi L; Mu X; Chen Y
    Analyst; 2011 May; 136(10):2077-83. PubMed ID: 21461410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyoxazoline-Conjugated l-Asparaginase: An Antibody-Production-Free Therapeutic Agent for Acute Lymphoblastic Leukemia.
    Yamada T; Ishimaru M; Shoji T; Tomiyasu H; Tochinai R; Taguchi K; Komatsu T
    ACS Appl Bio Mater; 2023 Dec; 6(12):5789-5797. PubMed ID: 38047730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Review on L-Asparaginase and Its Applications.
    Batool T; Makky EA; Jalal M; Yusoff MM
    Appl Biochem Biotechnol; 2016 Mar; 178(5):900-23. PubMed ID: 26547852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbial L-asparaginase as a promising enzyme for treatment of various cancers.
    Darvishi F; Jahanafrooz Z; Mokhtarzadeh A
    Appl Microbiol Biotechnol; 2022 Sep; 106(17):5335-5347. PubMed ID: 35871694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-asparaginase production review: bioprocess design and biochemical characteristics.
    Castro D; Marques ASC; Almeida MR; de Paiva GB; Bento HBS; Pedrolli DB; Freire MG; Tavares APM; Santos-Ebinuma VC
    Appl Microbiol Biotechnol; 2021 Jun; 105(11):4515-4534. PubMed ID: 34059941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor.
    Asselin BL; Lorenson MY; Whitin JC; Coppola DJ; Kende AS; Blakley RL; Cohen HJ
    Cancer Res; 1991 Dec; 51(24):6568-73. PubMed ID: 1742729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into the Microbial L-Asparaginases: from Production to Practical Applications.
    Sharma D; Singh K; Singh K; Mishra A
    Curr Protein Pept Sci; 2019; 20(5):452-464. PubMed ID: 30426897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A critical analysis of L-asparaginase activity quantification methods-colorimetric methods versus high-performance liquid chromatography.
    Magri A; Soler MF; Lopes AM; Cilli EM; Barber PS; Pessoa A; Pereira JFB
    Anal Bioanal Chem; 2018 Nov; 410(27):6985-6990. PubMed ID: 30155702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailoring structure-function properties of L-asparaginase: engineering resistance to trypsin cleavage.
    Kotzia GA; Lappa K; Labrou NE
    Biochem J; 2007 Jun; 404(2):337-43. PubMed ID: 17313368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering and Expression Strategies for Optimization of L-Asparaginase Development and Production.
    Shishparenok AN; Gladilina YA; Zhdanov DD
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.